You can legally receive a GLP-1 prescription — for Ozempic, Wegovy, Mounjaro, or Zepbound — through a telehealth platform without an in-person visit in most U.S. states. Platforms vary significantly in cost, which medications they offer, whether they use brand-name or compounded versions, and how closely they monitor your progress. Here is what to know before choosing one.
What Makes a GLP-1 Telehealth Platform Legitimate?
A legitimate platform must connect you with a licensed, U.S.-based prescriber — a physician, nurse practitioner, or physician assistant — who reviews your health history before writing any prescription. Per FDA labeling for Wegovy and Zepbound, prescribers are expected to evaluate BMI, weight-related comorbidities, and contraindications such as a personal or family history of medullary thyroid carcinoma.
- Prescriber credentials: Confirm the platform employs licensed clinicians in your state.
- Medication source: Branded FDA-approved drugs should come from licensed pharmacies. Compounded semaglutide or tirzepatide carries additional regulatory caveats (see below).
- Ongoing monitoring: Reputable services schedule follow-up visits and dose escalation check-ins.
- Transparent pricing: Total cost — consultation, medication, and any required lab work — should be disclosed upfront.
- No guarantees: Any platform promising specific weight-loss results violates FTC guidelines. The FTC took action in 2024 against companies making unsupported weight-loss drug claims.
How Do the Top Platforms Compare?
The table below reflects publicly available pricing and policies as of mid-2025. Costs change frequently — always verify directly with the platform before signing up.
| Platform | Medications Offered | Approx. Monthly Cost | Branded or Compounded | Insurance Accepted | Follow-Up Care |
|---|---|---|---|---|---|
| Hims & Hers | Compounded semaglutide | ~$199–$299 | Compounded | No | Messaging + check-ins |
| Ro Body | Wegovy, compounded semaglutide | ~$99 program fee + Rx cost | Both | Limited | Coaching + provider access |
| Noom Med | Wegovy, Ozempic, Zepbound | ~$149–$199 + Rx cost | Branded | Yes (some plans) | Behavioral coaching included |
| WeightWatchers Clinic | Wegovy, Zepbound, Ozempic | ~$99/mo + Rx cost | Branded | Yes (some plans) | Structured program |
| Found | Ozempic, Wegovy, Mounjaro, Zepbound | ~$99/mo + Rx cost | Branded | Yes (some plans) | Health coach + provider |
| Calibrate | Ozempic, Wegovy, Mounjaro, Zepbound | ~$199/mo (program) | Branded | Helps with submission | Metabolic coaching |
Most important point: Compounded semaglutide and tirzepatide are not FDA-approved drugs. The FDA has confirmed that semaglutide and tirzepatide are no longer on the shortage list as of early 2025, which means most compounded versions are no longer legally permitted under federal rules. If a platform is still offering compounded versions, ask specifically about their pharmacy's compliance status before proceeding.
What Is the Typical Onboarding Process?
Most platforms follow a similar intake sequence, though timelines vary. The week-by-week breakdown below reflects a typical experience:
| Week | What Happens |
|---|---|
| Week 1 | Complete intake questionnaire: medical history, current medications, BMI, goals. Pay consultation fee. |
| Week 1–2 | Async or video review by a licensed prescriber. Lab work may be requested (A1C, lipids, metabolic panel). |
| Week 2–3 | Prescription sent to in-network or mail-order pharmacy. Starting dose is typically the lowest labeled dose. |
| Week 4–5 | First follow-up check-in. Side effects reviewed. Dose escalation scheduled per FDA-labeled titration schedule. |
| Month 3+ | Ongoing monthly or quarterly provider visits. Insurance prior authorization support on many platforms. |
What About Insurance and Cost?
Branded GLP-1 medications are expensive without coverage. The list price for Wegovy is approximately $1,349 per month, and Zepbound is approximately $1,059 per month, according to manufacturer published pricing. Most commercial insurers cover these drugs only for qualifying diagnoses — obesity (BMI ≥30 or ≥27 with a comorbidity) for Wegovy and Zepbound, or type 2 diabetes for Ozempic and Mounjaro.
- Manufacturer savings programs: Novo Nordisk and Eli Lilly both offer savings cards that can reduce out-of-pocket costs to as low as $25/month for eligible commercially insured patients.
- Prior authorization: Most insurers require it. Platforms like Noom Med, Found, and Calibrate assist with PA paperwork.
- Medicare and Medicaid: Medicare Part D currently does not cover weight-loss drugs, though coverage for Wegovy for cardiovascular risk reduction is expanding following the 2023 SELECT trial results.
- Self-pay: If paying out of pocket, ask your prescriber about GoodRx or Cost Plus Drugs pricing for Ozempic, which is sometimes lower than the list price.
What Are the Eligibility Requirements?
FDA labeling sets the minimum clinical thresholds that any legitimate prescriber — telehealth or in-person — must follow. According to FDA prescribing information:
- Wegovy and Zepbound: Adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
- Ozempic: Adults with type 2 diabetes to improve glycemic control.
- Mounjaro: Adults with type 2 diabetes as an adjunct to diet and exercise.
- Universal contraindications: Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Platforms that skip these questions or approve everyone automatically are a red flag. A 2021 NEJM study (Wilding et al.) confirming semaglutide's efficacy enrolled participants who met these same clinical criteria — the labeled thresholds exist for safety reasons, not as arbitrary gatekeeping.
Frequently Asked Questions
Choosing the right telehealth platform for a GLP-1 prescription is a meaningful medical decision, not just a shopping exercise. Before signing up with any service, review their prescriber credentials, understand exactly what medication they are providing and from which pharmacy, confirm how dose escalation is managed, and get a full breakdown of costs including the medication itself. Your prescriber — whether reached through telehealth or in person — is your best resource for determining which GLP-1 medication fits your specific health profile, insurance situation, and treatment goals.
- FDA. Ozempic (semaglutide) Prescribing Information
- FDA. Wegovy (semaglutide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
- FDA. Zepbound (tirzepatide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- Joshi SS, et al. 'Telemedicine in the Era of COVID-19.' Journal of Allergy and Clinical Immunology: In Practice. 2020.
- Wilding JPH, et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- FTC. 'FTC Takes Action Against Companies Claiming to Sell Wegovy.' 2024
- HRSA Telehealth. 'Telehealth Policy.' https://telehealth.hhs.gov/providers/policy-changes-during-covid-19/prescribing-controlled-substances-via-telehealth